- Home
- FURY vs IRWD Comparison
FURY vs IRWD Comparison
Compare FURY & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- IRWD
- Stock Information
- Founded
- FURY 2008
- IRWD 1998
- Country
- FURY Canada
- IRWD United States
- Employees
- FURY N/A
- IRWD N/A
- Industry
- FURY Precious Metals
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- IRWD Health Care
- Exchange
- FURY Nasdaq
- IRWD Nasdaq
- Market Cap
- FURY 94.8M
- IRWD 111.2M
- IPO Year
- FURY N/A
- IRWD 2010
- Fundamental
- Price
- FURY $0.53
- IRWD $1.03
- Analyst Decision
- FURY Strong Buy
- IRWD Buy
- Analyst Count
- FURY 1
- IRWD 5
- Target Price
- FURY $1.40
- IRWD $4.94
- AVG Volume (30 Days)
- FURY 198.8K
- IRWD 1.5M
- Earning Date
- FURY 08-26-2025
- IRWD 08-07-2025
- Dividend Yield
- FURY N/A
- IRWD N/A
- EPS Growth
- FURY N/A
- IRWD N/A
- EPS
- FURY N/A
- IRWD N/A
- Revenue
- FURY N/A
- IRWD $308,519,000.00
- Revenue This Year
- FURY N/A
- IRWD N/A
- Revenue Next Year
- FURY N/A
- IRWD N/A
- P/E Ratio
- FURY N/A
- IRWD N/A
- Revenue Growth
- FURY N/A
- IRWD N/A
- 52 Week Low
- FURY $0.35
- IRWD $0.53
- 52 Week High
- FURY $0.59
- IRWD $5.21
- Technical
- Relative Strength Index (RSI)
- FURY 56.02
- IRWD 63.45
- Support Level
- FURY $0.47
- IRWD $0.81
- Resistance Level
- FURY $0.54
- IRWD $1.16
- Average True Range (ATR)
- FURY 0.02
- IRWD 0.11
- MACD
- FURY -0.00
- IRWD 0.02
- Stochastic Oscillator
- FURY 74.44
- IRWD 70.45
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.